CSF3 and acute myeloid leukemia: To evaluate the CR rates of refractory/relapsed AML in younger adults, the Japanese Adult Leukemia Study Group (JALSG) conducted a phase II study of FLAGM (fludarabine 15 mg/m2 every 12 h on days 1–4, Ara-C 2 g/m2 on days 1–4), G-CSF 300 μg/m2 on days 1–4, and mitoxantrone 10 mg/m2 on days 3–5 protocol [56].